Molbio Diagnostics Limited (MOLBIO)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Molbio Diagnostics' revenue was ₹399 Cr (+299.4% year on year, -28.8% on the previous quarter), and net profit ₹56.6 Cr (against a loss a year earlier); the operating margin was 22.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹399 | +299.4% | -28.8% |
| Operating profit | ₹91.6 | from loss | -42.4% |
| Net profit | ₹56.6 | from loss | -41.0% |
| EPS (₹) | 5.02 | from loss | -37.7% |
| Operating margin | 22.9% | — | — |
MOLBIO delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 8.22% of the MOLBIO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 16.7%. The price rose 10.15% on unusually low delivery, so more of the move than usual was intraday trading. It traded 2.4 times its average daily volume.
Delivery in the last 5 sessions: 23.8% · 18.4% · 18.5% · 22.3% · 8.2%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Molbio Diagnostics Limited has announced the closure of its trading window starting October 01, 2026, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The restriction applies to all designated persons, insiders, and their immediate relatives ahead of the declaration of unaudited financial results for the quarter ended September 30, 2026. The window will reopen 48 hours after the declaration of the financial results. The specific date for the Board Meeting to consider the results will be communicated separately.
- Trading window closes on October 01, 2026
- Window remains closed until 48 hours after the declaration of Q2 results
- Pertains to financial results for the quarter ended September 30, 2026
Molbio Diagnostics Limited has informed the exchanges that company officials will participate in a virtual group meeting with investors and analysts. The interaction is scheduled for Tuesday, September 22, 2026, starting at 11:00 AM IST. Management stated that discussions will focus on general business outlook and publicly available information, with no unpublished price sensitive information (UPSI) being shared.
- Virtual group meeting scheduled for September 22, 2026
- Meeting start time fixed at 11:00 AM IST onwards
- Discussion restricted to publicly available information with no UPSI to be shared
- Filing made under Regulation 30 of SEBI LODR Regulations, 2015
Molbio Diagnostics released the transcript of its maiden earnings call for Q1 FY27 post-IPO. The company reported a footprint of over 12,500 Truenat machines installed across 90+ countries and cumulative testing surpassing 40 million tests. Management confirmed a recently signed 2-year TB rate contract with the Government of India. In Q1 FY27, Molbio posted a revenue of ₹399.38 crore with a net profit of ₹56.63 crore.
- Installed base reached over 12,500 Truenat machines deployed across 90-plus countries
- Over 40 million tests conducted using the Truenat platform to date across 43 assays covering 30 diseases
- R&D investments expanded to more than ₹2.16 billion over the last 3 years, with 207 registered patents
- Secured a fresh 2-year rate contract for TB testing with the Government of India finalized in August 2026
Molbio Diagnostics Limited has announced a change in its Corporate Identification Number (CIN) from U33125GA2000PLC002909 to L33125GA2000PLC002909, following its equity share listing on NSE and BSE on August 17, 2026. Consequently, its status on the Ministry of Corporate Affairs (MCA) portal has been updated from 'Unlisted' to 'Listed'. The master data shows an authorized capital of Rs 20,00,00,000 and a paid-up capital of Rs 11,52,39,996. This is a purely administrative filing to formalize listed company status with the Registrar of Companies, Goa.
- Equity shares listed on NSE and BSE on August 17, 2026
- CIN changed to L33125GA2000PLC002909 from U33125GA2000PLC002909
- Company status on MCA portal updated from 'Unlisted' to 'Listed'
- Authorised capital stands at Rs 20,00,00,000 and paid-up capital at Rs 11,52,39,996
Molbio Diagnostics Limited has uploaded the audio recording of its earnings call held on September 08, 2026. The call pertained to the company's standalone and consolidated financial results for the quarter ended June 30, 2026. In Q1 FY27, Molbio reported revenue of Rs 399.38 cr and a net profit of Rs 56.63 cr. The audio recording is accessible via the company's website.
- Earnings conference call conducted on September 08, 2026
- Audio recording covers financial results for the quarter ended June 30, 2026
- Recording made accessible to the public on www.molbiodiagnostics.com pursuant to SEBI regulations
Molbio Diagnostics released its Q1 FY27 investor presentation following its recent listing on August 17, 2026. Total income surged to ₹411.5 crore compared to ₹100.5 crore in Q1 FY26, driven by higher Truenat test-kit volumes (6.2 million units vs 0.8 million units). EBITDA turned positive to ₹103.7 crore (25.2% margin) against an EBITDA loss of ₹14.5 crore in Q1 FY26, while PAT stood at ₹52.7 crore compared to a net loss of ₹23.9 crore. Performance also benefited from ₹57 crore of deferred export orders from Q4 FY26 recognized this quarter.
- Q1 FY27 Total Income grew to ₹411.5 Cr vs ₹100.5 Cr in Q1 FY26
- EBITDA swung to ₹103.7 Cr (25.2% margin) from a loss of ₹14.5 Cr in Q1 FY26
- PAT turned positive at ₹52.7 Cr against a net loss of ₹23.9 Cr in Q1 FY26
- Truenat test-kit volumes surged to 6.2 Mn units in Q1 FY27 from 0.8 Mn units in Q1 FY26
- Results included ~₹57 Cr of deferred Q4 FY26 export orders recognized in Q1 FY27
Molbio Diagnostics announced its Q1 FY27 results (its first after listing on August 17, 2026), posting Total Income of ₹411.48 Cr compared to ₹100.47 Cr in Q1 FY26. The company turned profitable with an EBITDA of ₹103.68 Cr (25.20% margin) vs an EBITDA loss of ₹14.50 Cr in Q1 FY26, and a PAT of ₹52.74 Cr vs a net loss of ₹23.94 Cr in Q1 FY26. Performance was driven by Truenat test-kit volume expansion to 6.24 Mn units (up from 0.79 Mn in Q1 FY26), alongside the recognition of ₹57 Cr in deferred export orders from Q4 FY26.
- Total Income surged to ₹411.48 Cr in Q1 FY27 vs ₹100.47 Cr in Q1 FY26
- EBITDA turned positive to ₹103.68 Cr (25.20% margin) vs an EBITDA loss of ₹14.50 Cr in Q1 FY26
- PAT stood at ₹52.74 Cr compared to a net loss of ₹23.94 Cr in Q1 FY26
- Truenat test-kit sales reached 6.24 Mn units vs 0.79 Mn units in Q1 FY26
- Deferred export orders of ~₹57 Cr from Q4 FY26 were recognized in Q1 FY27
Molbio Diagnostics Limited announced the outcome of its Board of Directors meeting held on September 5, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, subject to limited review by statutory auditors. Additionally, the Board authorized key managerial personnel, including the CEO, CTO, CFO, and Company Secretary, to determine the materiality of events and disclosures under Regulation 30(5) of SEBI LODR Regulations.
- Board approved unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
- Meeting commenced at 11:47 AM and concluded at 04:00 PM on September 5, 2026
- Four Key Managerial Personnel authorized under Regulation 30(5) for determining disclosure materiality
Molbio Diagnostics Limited has scheduled an earnings conference call for Tuesday, September 8, 2026, at 04:00 PM IST. The management team will discuss the financial performance for the first quarter ended June 30, 2026 (Q1 FY27). Key senior executives, including the CEO, CTO, and CFO, will participate in the call.
- Earnings conference call scheduled for September 8, 2026, at 04:00 PM IST
- Meeting intended to discuss financial results for the quarter ended June 30, 2026 (Q1 FY27)
- Senior management including CEO Sriram Natarajan and CFO Manan Bimal Khokhani to participate
Molbio Diagnostics Limited reported the outcome of its Board of Directors meeting held on August 27, 2026. The Board designated Mr. Darshan Raghunath Karekar as the Compliance Officer under SEBI (Prohibition of Insider Trading) Regulations, 2015. Mr. Karekar is already the existing Compliance Officer under Regulation 6 of SEBI LODR Regulations. The brief meeting commenced at 04:56 PM and concluded at 05:08 PM.
- Board meeting conducted on August 27, 2026, lasting 12 minutes (04:56 PM to 05:08 PM)
- Mr. Darshan Raghunath Karekar designated as Compliance Officer under SEBI (PIT) Regulations, 2015
- Existing role as Compliance Officer under Regulation 6 of SEBI LODR continues unchanged
Molbio Diagnostics Limited has announced the closure of its trading window for insiders and designated persons starting August 21, 2026. The closure is in compliance with SEBI Insider Trading regulations ahead of the declaration of financial results for the quarter ended June 30, 2026. The window will reopen 48 hours after the declaration of the unaudited financial results. The specific date for the board meeting to approve the results will be announced separately.
- Trading window closes effective August 21, 2026
- Applies to all insiders, designated persons, and their immediate relatives
- Trading window reopens 48 hours after Q1 financial results declaration
- Results pertain to the quarter ended June 30, 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
